Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide for hospitalized pregnant or postpartum adults with COVID-19
ACTRN12621001585819Phase 3Not yet recruiting
- Sponsor
- Monash Health
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of budesonide in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Monash Health. Primary endpoint: Primary composite clinical deterioration endpoint. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
budesonide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12621001585819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001585819.